Discover and read the best of Twitter Threads about #Cadila
Most recents (4)
#Cadila Healthcare conducted their conference call yesterday for Q4 FY2021
"Cadila is 2nd larget growing company in Pharma space"
Here are the key takeaways 😃
"Cadila is 2nd larget growing company in Pharma space"
Here are the key takeaways 😃
Business Updates:
• India business grew 20% (includes human health, consumer wellness, & animal wellness)- 16.4BilRs.
• US (generic and Sepciality)- 16.03Bill Rs. QoQ decline
• Emerging Market growth- 11%: 2.93BilRs Sales.
• Launched 7 new product and approvals of 9 product.
• India business grew 20% (includes human health, consumer wellness, & animal wellness)- 16.4BilRs.
• US (generic and Sepciality)- 16.03Bill Rs. QoQ decline
• Emerging Market growth- 11%: 2.93BilRs Sales.
• Launched 7 new product and approvals of 9 product.
Revenue Mix:
• Human Health (India)- 21% growth (YoY).- 11.04BilRs
• Branded Generic Business grew 24% YoY
• Gained market share in Pain Mgmt, Anti-Effective, Anti-Diabetic.
• Market Share in Gyno, Pain Mgmt, Respiratory was maintained.
• Animal Health- 17% growth.
• Human Health (India)- 21% growth (YoY).- 11.04BilRs
• Branded Generic Business grew 24% YoY
• Gained market share in Pain Mgmt, Anti-Effective, Anti-Diabetic.
• Market Share in Gyno, Pain Mgmt, Respiratory was maintained.
• Animal Health- 17% growth.
My analysis of the paper released by #BharatBiotech researchers & the Press Statement by the Drugs Controller General of India (DCGI) on Restricted Emergency approval of 1out of 3 COVID-19 virus vaccine from Bharat Biotech: A thread...
1. PIB "The Phase III efficacy trial was initiated in India in 25,800 volunteers & till date, ~22,500 participants have been vaccinated across the country"
Fact check "A total of 25,800 subjects will be enrolled & randomized in a 1:1 ratio to receive BBV152B vaccine and control"
Fact check "A total of 25,800 subjects will be enrolled & randomized in a 1:1 ratio to receive BBV152B vaccine and control"
1. Fact check contd...
A 1:1 ratio means half of 25800 will be enrolled, of which only (almost) 12900 will be given BBV152B vaccine and the other 12900 will be given a placebo, i.e. Phosphate buffered saline PBS with Alum gel (without antigen)
Source: CTRI
A 1:1 ratio means half of 25800 will be enrolled, of which only (almost) 12900 will be given BBV152B vaccine and the other 12900 will be given a placebo, i.e. Phosphate buffered saline PBS with Alum gel (without antigen)
Source: CTRI
Respected all sir
I have observe that many times after high volume candle formed stocks price drop and that high volume candle's high is protected and break that high by another high volume candle only.
Here are some examples.
I have cover all large, mid and small cap stocks
I have observe that many times after high volume candle formed stocks price drop and that high volume candle's high is protected and break that high by another high volume candle only.
Here are some examples.
I have cover all large, mid and small cap stocks
National Institute of Virology, Pune has successfully developed the 1st indigenous anti-SARS-CoV-2 human IgG ELISA test kit for antibody detection of #COVID19 .
This robust test will play a critical role in surveillance of proportion of population exposed to #SARSCoV2 infection
This robust test will play a critical role in surveillance of proportion of population exposed to #SARSCoV2 infection
This kit was validated at 2 sites in Mumbai & has high sensitivity & accuracy. Besides,it has the advantage of testing 90 samples together in a single run of 2.5 hours, so that healthcare professionals can proceed quickly with necessary next steps on their patients’ triage paths.
#ELISA based testing is easily possible even at district level. The @icmr_niv technology has been transferred to #Zydus #Cadila for mass-scale production.
The Drug Controller General has granted commercial production & marketing permission to Zydus. #COVID19Updates #SARS_CoV_2
The Drug Controller General has granted commercial production & marketing permission to Zydus. #COVID19Updates #SARS_CoV_2
